RBM10 and cancer: These results not only demonstrate that the cancer-derived mutant RBM10-I316F loses its ability to suppress c-Myc and consequently to inhibit tumor growth but also suggest that this mutant might gain an ability to promote cancer growth potentially by inhibiting its wild-type counterpart.